NCT01804335View on ClinicalTrials.gov

CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Lymphoma
Interventions
DRUG

CD5789 0.01% Cream

CD5789 0.01% cream applied on the lesions once daily for twelve weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Galderma R&D
All Listed Sponsors
collaborator

Galderma R&D

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01804335 - CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) | Biotech Hunter | Biotech Hunter